171 related articles for article (PubMed ID: 34629822)
1. Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer.
Rah B; Banday MA; Bhat GR; Shah OJ; Jeelani H; Kawoosa F; Yousuf T; Afroze D
World J Gastroenterol; 2021 Sep; 27(36):6093-6109. PubMed ID: 34629822
[TBL] [Abstract][Full Text] [Related]
2. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
3. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Xu XL; Yu J; Zhang HY; Sun MH; Gu J; Du X; Shi DR; Wang P; Yang ZH; Zhu JD
World J Gastroenterol; 2004 Dec; 10(23):3441-54. PubMed ID: 15526363
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
Mishra NK; Guda C
Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
[TBL] [Abstract][Full Text] [Related]
5. Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours.
Ahmad F; Surve P; Natarajan S; Patil A; Pol S; Patole K; Das BR
Cancer Genet; 2020 Feb; 241():42-50. PubMed ID: 31653608
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
[TBL] [Abstract][Full Text] [Related]
7. Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
Laskar RS; Ghosh SK; Talukdar FR
Mol Carcinog; 2015 Dec; 54(12):1786-95. PubMed ID: 25418895
[TBL] [Abstract][Full Text] [Related]
8. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
9. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
Ye C; Shrubsole MJ; Cai Q; Ness R; Grady WM; Smalley W; Cai H; Washington K; Zheng W
Oncol Rep; 2006 Aug; 16(2):429-35. PubMed ID: 16820927
[TBL] [Abstract][Full Text] [Related]
11. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
[TBL] [Abstract][Full Text] [Related]
12. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.
Jiao L; Zhu J; Hassan MM; Evans DB; Abbruzzese JL; Li D
Pancreas; 2007 Jan; 34(1):55-62. PubMed ID: 17198183
[TBL] [Abstract][Full Text] [Related]
13. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
14. An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression.
Khan AA; Liu X; Yan X; Tahir M; Ali S; Huang H
Cancer Metastasis Rev; 2021 Mar; 40(1):245-272. PubMed ID: 33423164
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers of pancreatic cancer: development and clinical relevance.
Fry LC; Mönkemüller K; Malfertheiner P
Langenbecks Arch Surg; 2008 Nov; 393(6):883-90. PubMed ID: 18266003
[TBL] [Abstract][Full Text] [Related]
17. Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms.
Yoshida K; Nagasaka T; Umeda Y; Tanaka T; Kimura K; Taniguchi F; Fuji T; Shigeyasu K; Mori Y; Yanai H; Yagi T; Goel A; Fujiwara T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1557-69. PubMed ID: 27095449
[TBL] [Abstract][Full Text] [Related]
18. Association of aberrant methylation at promoter regions of tumor suppressor genes with placental pathologies.
Rahat B; Thakur S; Hamid A; Bagga R; Kaur J
Epigenomics; 2016 Jun; 8(6):767-87. PubMed ID: 27337502
[TBL] [Abstract][Full Text] [Related]
19. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]